Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Transgene S.A. TRGNF OTC

Other OTC • Healthcare • Biotechnology • FR • USD

SharesGrow Score
24/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Transgene S.A. (TRGNF) is a Biotechnology company in the Healthcare sector, currently trading at $1.00. It has a SharesGrow Score of 23/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $136,947, +0.4%/yr average growth. Net income is $38M (loss), growing at -10.2%/yr. Net profit margin is -27390.1% (negative). Gross margin is 0% (+929 pp trend).

Balance sheet: total debt is $2M against $122M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 9.62 (strong liquidity). Debt-to-assets is 1.5%. Total assets: $139M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 30/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 15/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

TRGNF SharesGrow Score Overview

31/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 30/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 15/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — TRGNF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
30/100
TRGNF: +0.4%/yr revenue is, -10.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet TRGNF: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 9.62 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
15/100
TRGNF: Gross margin is 0% (+929 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 15/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
TRGNF: Net profit margin is -27390.1%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.7-1.62
Volume100
Avg Volume (30D)47
Market Cap$144.2M
Beta (1Y)0.65
Share Statistics
EPS (TTM)-0.26
Shares Outstanding$144.32M
IPO Date2021-01-08
Employees144
CEOAlessandro Riva
Financial Highlights & Ratios
Revenue (TTM)$136.95K
EBITDA$-39.76M
Net Income$-37.51M
Operating Income$-41.05M
Total Cash$111.82M
Total Debt$2.06M
Net Debt$-4.6M
Total Assets$138.77M
Price / Earnings (P/E)-3.8
Price / Sales (P/S)1052.96
Analyst Forecast
Company Info
CountryFR
ExchangeOther OTC
CurrencyUSD
ISINFR0005175080

Price Chart

Track all markets on TradingView
TRGNF
Transgene S.A. ↗  ·  Other OTC
Healthcare • Biotechnology
0.70 52WK RANGE 1.62

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message